These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 23664820)
1. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820 [TBL] [Abstract][Full Text] [Related]
2. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632 [TBL] [Abstract][Full Text] [Related]
3. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593 [TBL] [Abstract][Full Text] [Related]
4. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793 [TBL] [Abstract][Full Text] [Related]
5. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. Margel D; Nandy I; Wilson TH; Castro R; Fleshner N J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. Wong LM; Ferrara S; Alibhai SM; Evans A; Van der Kwast T; Trottier G; Timilshina N; Toi A; Kulkarni G; Hamilton R; Zlotta A; Fleshner N; Finelli A Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):69-74. PubMed ID: 25487136 [TBL] [Abstract][Full Text] [Related]
7. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance. Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083 [TBL] [Abstract][Full Text] [Related]
8. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models. Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446 [TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of perineural invasion and race in men considering active surveillance. Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869 [TBL] [Abstract][Full Text] [Related]
10. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance. Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398 [TBL] [Abstract][Full Text] [Related]
11. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077 [TBL] [Abstract][Full Text] [Related]
12. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511 [TBL] [Abstract][Full Text] [Related]
13. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591 [TBL] [Abstract][Full Text] [Related]
15. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ; Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565 [TBL] [Abstract][Full Text] [Related]
16. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975 [TBL] [Abstract][Full Text] [Related]
17. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. Patel AA; Chen MH; Renshaw AA; D'Amico AV JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498 [TBL] [Abstract][Full Text] [Related]
18. Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates? Wong LM; Trottier G; Toi A; Lawrentschuk N; Van der Kwast TH; Zlotta A; Kulkarni G; Hamilton R; Trachtenberg J; Evans A; Timilshina N; Fleshner NE; Finelli A Urology; 2013 Aug; 82(2):405-9. PubMed ID: 23735610 [TBL] [Abstract][Full Text] [Related]
19. A multi-institutional evaluation of active surveillance for low risk prostate cancer. Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624 [TBL] [Abstract][Full Text] [Related]
20. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]